Thymoquinone Blocks pSer/pThr Recognition by Plk1 Polo-Box Domain As a Phosphate Mimic
Citations Over TimeTop 10% of 2012 papers
Abstract
Phosphorylation-dependent protein-protein interaction has rarely been targeted in medicinal chemistry. Thymoquinone, a naturally occurring antitumor agent, disrupts prephosphorylated substrate recognition by the polo-box domain of polo-like kinase 1, a key mitotic regulator responsible for various carcinogenesis when overexpressed. Here, crystallographic studies reveal that the phosphoserine/phosphothreonine recognition site of the polo-box domain is the binding pocket for thymoquinone and its analogue poloxime. Both small molecules displace phosphopeptides bound with the polo-box domain in a slow but noncovalent binding mode. A conserved water bridge and a cation-π interaction were found as their competition strategy against the phosphate group. This mechanism sheds light on small-molecule intervention of phospho-recognition by the polo-box domain of polo-like kinase 1 and other phospho-binding proteins in general.
Related Papers
- → Progress in the Discovery of Polo-like Kinase Inhibitors(2005)111 cited
- → Inhibitors of the Polo‐Box Domain of Polo‐Like Kinase 1(2015)26 cited
- → A review of Plks: Thinking outside the (polo) box(2022)20 cited
- → BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)(2009)27 cited
- Preclinical Research and Early Clinical Research of Polo-like Kinase 1 Inhibitors(2011)